PureTech Health Statistics
Total Valuation
PureTech Health has a market cap or net worth of EUR 343.11 million. The enterprise value is 198.09 million.
| Market Cap | 343.11M |
| Enterprise Value | 198.09M |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 241.68M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -11.33% |
| Shares Change (QoQ) | -1.00% |
| Owned by Insiders (%) | 3.58% |
| Owned by Institutions (%) | 75.31% |
| Float | 167.83M |
Valuation Ratios
The trailing PE ratio is 7.95.
| PE Ratio | 7.95 |
| Forward PE | n/a |
| PS Ratio | 63.05 |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 4.59 |
| EV / Sales | 37.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.32 |
Financial Position
The company has a current ratio of 8.49, with a Debt / Equity ratio of 0.44.
| Current Ratio | 8.49 |
| Quick Ratio | 8.35 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.63 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 9.44% and return on invested capital (ROIC) is -14.92%.
| Return on Equity (ROE) | 9.44% |
| Return on Assets (ROA) | -12.95% |
| Return on Invested Capital (ROIC) | -14.92% |
| Return on Capital Employed (ROCE) | -22.90% |
| Revenue Per Employee | 97,177 |
| Profits Per Employee | 770,577 |
| Employee Count | 56 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, PureTech Health has paid 2.61 million in taxes.
| Income Tax | 2.61M |
| Effective Tax Rate | 8.76% |
Stock Price Statistics
The stock price has decreased by -29.29% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -29.29% |
| 50-Day Moving Average | 1.45 |
| 200-Day Moving Average | 1.50 |
| Relative Strength Index (RSI) | 49.24 |
| Average Volume (20 Days) | 500 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PureTech Health had revenue of EUR 5.44 million and earned 43.15 million in profits. Earnings per share was 0.17.
| Revenue | 5.44M |
| Gross Profit | -41.56M |
| Operating Income | -99.97M |
| Pretax Income | 29.76M |
| Net Income | 43.15M |
| EBITDA | -98.53M |
| EBIT | -99.97M |
| Earnings Per Share (EPS) | 0.17 |
Balance Sheet
The company has 282.09 million in cash and 139.28 million in debt, giving a net cash position of 142.81 million.
| Cash & Cash Equivalents | 282.09M |
| Total Debt | 139.28M |
| Net Cash | 142.81M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 314.22M |
| Book Value Per Share | 1.33 |
| Working Capital | 258.70M |
Cash Flow
In the last 12 months, operating cash flow was -85.40 million and capital expenditures -9,367, giving a free cash flow of -85.41 million.
| Operating Cash Flow | -85.40M |
| Capital Expenditures | -9,367 |
| Free Cash Flow | -85.41M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,837.01% |
| Pretax Margin | 546.82% |
| Profit Margin | 792.96% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PureTech Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 11.33% |
| Shareholder Yield | 11.33% |
| Earnings Yield | 12.58% |
| FCF Yield | -24.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PureTech Health has an Altman Z-Score of 1.44 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.44 |
| Piotroski F-Score | 4 |